Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.
Walker, D.P., Zawistoski, M.P., McGlynn, M.A., Li, J.C., Kung, D.W., Bonnette, P.C., Baumann, A., Buckbinder, L., Houser, J.A., Boer, J., Mistry, A., Han, S., Xing, L., Guzman-Perez, A.(2009) Bioorg Med Chem Lett 19: 3253-3258
- PubMed: 19428251 
- DOI: https://doi.org/10.1016/j.bmcl.2009.04.093
- Primary Citation of Related Structures:  
3H3C - PubMed Abstract: 
The synthesis, in vitro properties, and in vivo pharmacokinetics for a series of sulfoximine-substituted trifluoromethylpyrimidines as inhibitors of proline-rich tyrosine kinase, a target for the possible treatment of osteoporosis, are described. These compounds were prepared as surrogates of the corresponding sulfone compound 1 ...